Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors.
OBJECTIVE
To evaluate the prevalence and severity of steatosis and possible interactions between steatosis, host factors, viral factors, and treatment for HIV infection in HIV-hepatitis C virus (HCV) coinfected patients.


METHODS
Steatosis was assessed among 395 HIV-HCV coinfected patients who were enrolled in the ANRS trial HC02 Ribavic and for whom histological data were available. Steatosis was graded as follows: 0 (none); 1 (< 30% hepatocytes containing fat); 2 (30-70%); 3 (> 70%).


RESULTS
Steatosis was present in 241 patients (61%), of whom 149 (38%) had grade 1, 64 (16%) grade 2 and 28 (7%) grade 3. In multivariate analysis, the following five independent risk factors were associated with steatosis: HCV genotype 3 [odds ratio (OR), 3.02; 95% confidence interval (CI), 1.91-4.79; P < 0.0001], the mean METAVIR fibrosis score (OR, 1.43; 95% CI, 1.11-1.84; P = 0.0053), the body mass index (BMI; OR, 1.13; 95% CI, 1.05-1.21; P = 0.0013), HCV viral load (OR. 1.65; 95% CI, 1.22-2.23; P = 0.0012) and ferritin (OR, 1.13; 95% CI, 1.06-1.21; P < 0.0003). As HCV genotype 3 was a risk factor for steatosis, further exploratory analyses were stratified according to the HCV genotype (1 and 3). Factors independently associated with steatosis were BMI and HCV viral load in patients with HCV genotype 3 infection and the mean METAVIR fibrosis score, the BMI and ferritin in patients with HCV genotype 1 infection.


CONCLUSIONS
Steatosis is particularly frequent in HIV-HCV coinfected patients, who appear to have the same risk factors for steatosis as HCV monoinfected patients. None of the characteristics of HIV infection, including antiretroviral therapy, was independently associated with steatosis.
Groupe Hospitalier Universitaire Est, Université Paris 6, INSERM V707, Paris, France. firouze.bani-sadr@tnn.ap-hop-paris.fr
Firouzé
F
Bani-Sadr
Fabrice
F
Carrat
Pierre
P
Bedossa
Lionel
L
Piroth
Patrice
P
Cacoub
Christian
C
Perronne
Claude
C
Degott
Stanislas
S
Pol
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D044966:Anti-Retroviral Agents / Q000627:therapeutic use; D005234:Fatty Liver / Q000150:complications* / Q000473:pathology; D005260:Female; D005838:Genotype; D015658:HIV Infections / Q000150:complications* / Q000235:genetics / Q000473:pathology; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000473:pathology; D006801:Humans; D008103:Liver Cirrhosis / Q000473:pathology / Q000821:virology; D008297:Male; D012333:RNA, Messenger / Q000032:analysis; D012367:RNA, Viral / Q000032:analysis; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D019562:Viral Load
D019380:Anti-HIV Agents; D044966:Anti-Retroviral Agents; D012333:RNA, Messenger; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors